Thursday, July 28, 2022 Replicating RNA Vaccine Generates Unexpected Immune Response Against CCHFV in Mice Scanning electron micrograph of Crimean-Congo hemorrhagic fever (CCHF) viral particles (yellow) budding from the surface of cultured epithelial cells from a patient. Credit: NIAID NIAID scientists and HDT Bio colleagues have shown that an experimental replicating RNA vaccine generates an unexpected immune response against Crimean-Congo hemorrhagic fever virus in mice. They published the study on July 27 in The Lancet's eBioMedicine. Combining the viral nucleoprotein and glycoproteins in the vaccine protected against disease and viral replication in a single dose. Unexpectedly, protection was driven by non-neutralizing antibodies to the internal nucleoprotein. CCHFV, primarily spread by tick bites, is endemic in Africa, the Balkans, the Middle East and Asia – though Spain drew attention from public health experts when it reported a case on July 21. National Institute of Allergy and Infectious Diseases  |  National Institutes of Health Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help. This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID).                             This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107